IRD OPUS GENETICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, OPUS GENETICS INC reported revenue of $755K (down 73.8% from a year earlier), net income of −$8.10M and diluted EPS of −$0.14; over the last four quarters revenue was $9.86M and net income −$108M; for the fiscal year ended December 2025 revenue was $14.2M, up 29.1% on the year before.
IRD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $14.2M, gross profit n/a, operating income −$38.6M, net income −$49.6M (margin -349.3%), EPS −$0.80
- Fiscal year ended Dec 2024: revenue $11.0M, gross profit n/a, operating income −$62.1M, net income −$57.5M (margin -523.4%), EPS −$2.15
- Fiscal year ended Dec 2023: revenue $19.0M, gross profit n/a, operating income −$10.6M, net income −$9.99M (margin -52.4%), EPS −$0.46
- Fiscal year ended Dec 2022: revenue $39.9M, gross profit n/a, operating income $18.2M, net income $17.9M (margin 44.9%), EPS $0.87
- Fiscal year ended Dec 2021: revenue $589K, gross profit n/a, operating income −$22.7M, net income −$56.7M (margin -9625.3%), EPS −$3.82
IRD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $755K (down 73.8% year over year), net income −$8.10M, EPS −$0.14
- Quarter ended Mar 31, 2026: revenue $2.16M (down 50.6% year over year), net income −$65.5M, EPS −$0.75
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.87M (down 10.2% year over year), net income −$16.5M, EPS −$0.19
- Quarter ended Sep 30, 2025: revenue $3.08M (down 20.4% year over year), net income −$17.5M, EPS −$0.25
- Quarter ended Jun 30, 2025: revenue $2.88M (up 159.2% year over year), net income −$7.42M, EPS −$0.12
- Quarter ended Mar 31, 2025: revenue $4.37M (up 155.4% year over year), net income −$8.19M, EPS −$0.24
- Quarter ended Dec 31, 2024 (from the annual report): revenue $4.30M (up 154.4% year over year), net income −$35.1M, EPS −$1.27
- Quarter ended Sep 30, 2024: revenue $3.87M (down 67.6% year over year), net income −$7.53M, EPS −$0.29
- Quarter ended Jun 30, 2024: revenue $1.11M (down 69.7% year over year), net income −$7.77M, EPS −$0.30
- Quarter ended Mar 31, 2024: revenue $1.71M (down 2.2% year over year), net income −$7.11M, EPS −$0.29
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.69M (down 95.8% year over year), net income −$4.80M, EPS −$0.19
- Quarter ended Sep 30, 2023: revenue $11.9M, net income $5.56M, EPS $0.25
- Quarter ended Jun 30, 2023: revenue $3.67M, net income −$4.96M, EPS −$0.24
- Quarter ended Mar 31, 2023: revenue $1.75M, net income −$5.79M, EPS −$0.28
- Quarter ended Dec 31, 2022 (from the annual report): revenue $39.9M, net income $33.9M, EPS $1.69
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$4.53M, EPS −$0.22
- Quarter ended Jun 30, 2022: revenue $0 (down 100.0% year over year), net income −$4.93M, EPS −$0.25
- Quarter ended Mar 31, 2022: revenue $0, net income −$6.60M, EPS −$0.35
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$6.31M, EPS $0.52
- Quarter ended Sep 30, 2021: revenue $489K, net income −$4.23M, EPS −$0.25
IRD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$35.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$25.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.11M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $14.3M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$19.4M, share buybacks n/a
IRD balance sheet
- Jun 30, 2026: cash $88.8M, total assets $93.0M, total liabilities $106M, shareholders' equity −$13.0M
- Mar 31, 2026: cash $60.0M, total assets $66.8M, total liabilities $87.9M, shareholders' equity −$45.8M, long-term debt $1.20M
- Dec 31, 2025: cash $45.1M, total assets $50.2M, total liabilities $34.9M, shareholders' equity $15.3M, long-term debt $1.13M
- Sep 30, 2025: cash $30.8M, total assets $36.1M, total liabilities $30.2M, shareholders' equity $5.97M, long-term debt $1.07M
- Jun 30, 2025: cash $32.4M, total assets $38.7M, total liabilities $21.2M, shareholders' equity $17.5M, long-term debt $1.00M
- Mar 31, 2025: cash $41.8M, total assets $48.2M, total liabilities $24.3M, shareholders' equity $5.07M
- Dec 31, 2024: cash $30.3M, total assets $36.9M, total liabilities $11.3M, shareholders' equity $6.72M, long-term debt $0
- Sep 30, 2024: cash $36.6M, total assets $40.4M, total liabilities $6.09M, shareholders' equity $34.3M
What is IRD's revenue?
OPUS GENETICS INC reported $9.86M of revenue over its last four quarters, through June 30, 2026.
Is IRD profitable?
No. OPUS GENETICS INC lost $108M over the last four quarters.
What is IRD's EPS?
Diluted earnings per share over the last four quarters were −$1.33; −$0.14 in the latest quarter.